NCT06711523 2025-11-25
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
Kexing Biopharm Co., Ltd.
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT06616571 2024-09-27
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Qilu Pharmaceutical Co., Ltd.
Phase 4 Recruiting
NCT05249894 2022-03-28
LAM-SEPSIS
A.O.U. Città della Salute e della Scienza
Unknown
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT03823950 2020-03-13
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
University of Mississippi Medical Center
Phase 4 Unknown
NCT04101760 2019-10-08
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
Peking Union Medical College Hospital
Phase 3 Unknown
NCT04000711 2019-06-27
Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia
Hospital Infantil de Mexico Federico Gomez
Phase NA Completed
NCT02178475 2018-07-23
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
Amgen
Completed
NCT01574235 2015-07-28
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
Hospira, now a wholly owned subsidiary of Pfizer
Completed